Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens-Reference-Cited by-同舟云学术

Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens

Published:2023-01 Issue: Volume:126 Page:64-72
ISSN:1201-9712
Container-title:International Journal of Infectious Diseases
language:en
Short-container-title:International Journal of Infectious Diseases

Author:

Kanokudom Sitthichai^ORCID,Chansaenroj Jira,Suntronwong Nungruthai^ORCID,Assawakosri Suvichada^ORCID,Yorsaeng Ritthideach^ORCID,Nilyanimit Pornjarim,Aeemjinda Ratchadawan,Khanarat Nongkanok,Vichaiwattana Preeyaporn,Klinfueng Sirapa,Thongmee Thanunrat,Katanyutanon Apirat,Thanasopon Wichai,Arayapong Jirawan,Withaksabut Withak,Srimuan Donchida,Thatsanatorn Thaksaporn,Sudhinaraset Natthinee,Wanlapakorn Nasamon^ORCID,Honsawek Sittisak,Poovorawan Yong

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference31 articles.

1. Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study;Ai;Emerg Microbes Infect,2022

2. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination;Assawakosri;Int J Infect Dis,2022

3. Neutralizing activities against the omicron variant after a heterologous booster in healthy adults receiving two doses of CoronaVac vaccination;Assawakosri;J Infect Dis,2022

4. Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages;Bhiman;bioRxiv,2022

5. Specific anti-SARS-CoV-2 humoral and cellular immune responses after booster dose of BNT162b2 Pfizer-BioNTech mRNA-based vaccine: integrated study of adaptive immune system components;Busà;Front Immunol,2022

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac®) as a Booster Dose against COVID-19 in Indonesian Adults;Vaccines;2024-05-14

2. SAFETY AND IMMUNOGENICITY OF A PHH-1V BOOSTER DOSE AFTER DIFFERENT PRIME VACCINATION SCHEMES AGAINST COVID-19: PHASE III CLINICAL TRIAL FINAL RESULTS UP TO ONE YEAR;2024-05-14

3. Prognostic Factors Associated with the Severe Course of a New Coronavirus Infection;Ural Medical Journal;2024-03-07

4. Editorial: COVID-19 booster vaccination: increasing immunity against life-threatening infection;Frontiers in Public Health;2024-01-09

5. Real-World Study: Hybrid Immunity against SARS-CoV-2 Influences the Antibody Levels and Persistency Lasting More than One Year;Vaccines;2023-11-07